Physician profile
Omar Husseini
NPI 1467740894
$65,795.42
in general payments reported to CMS, 2019-2025
36 companies · $3,721 in 2025
The $3,721 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,827 · 2020: $11K · 2021: $12K · 2022: $16K · 2023: $12K · 2024: $8,018 · 2025: $3,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Food and Beverage: $5,914 · Travel and Lodging: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Food and Beverage | $5,913.85 |
| Travel and Lodging | $2,228.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $42,250.05 | 2019-2023 | Definity |
| Edwards Lifesciences Corporation | $14,108.46 | 2019-2025 | Pascal, Evoque |
| Abbott Laboratories | $2,442.71 | 2019-2025 | Triclip, Mitraclip, Cardiomems |
| Boston Scientific Corporation | $2,113.56 | 2019-2025 | Watchman Flx, Watchman Access System, Watchdog |
| Novartis Pharmaceuticals Corporation | $1,275.63 | 2019-2025 | |
| Amgen INC. | $523.57 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $504.31 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $305.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $262.17 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.60 | 2019-2023 | Jardiance |
| Pfizer INC. | $172.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $171.10 | 2019-2024 | Wainua, Brilinta |
| Inspire Medical Systems, INC. | $158.90 | 2023-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $126.07 | 2019-2024 | Evkeeza |
| Mylan Specialty L.P. | $125.00 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $120.49 | 2019-2025 | Nuvision Ice Catheter |
| Penumbra, INC. | $117.31 | 2023 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $105.94 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $102.48 | 2019 | |
| Chiesi USA, INC. | $94.97 | 2021-2025 | Kengreal, Cleviprex, Curosurf |
| Atricure, INC. | $75.20 | 2019-2023 | |
| Scpharmaceuticals INC. | $68.61 | 2024 | |
| Novo Nordisk INC | $50.23 | 2024-2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $39.43 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $38.05 | 2024 | Arcalyst |
| Cvrx, INC. | $33.95 | 2023-2024 | Barostim Neo System |
| Bolton Medical INC | $32.33 | 2021 | |
| Lundbeck LLC | $29.43 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.55 | 2023 | |
| Tactile Systems Technology INC | $26.64 | 2024 | Entre Plus, Flexitouch Plus |
| Gilead Sciences, INC. | $26.23 | 2019 | |
| Astellas Pharma US INC | $22.23 | 2019 | |
| Argon Medical Devices, INC. | $20.39 | 2025 | Clot Management |
| Kiniksa Pharmaceuticals, LTD. | $16.82 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $14.22 | 2021 | |
| Vifor Pharma, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Husseini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.